Last updated: March 1, 2026
What is the drug identified by NDC 00527-2961?
NDC 00527-2961 corresponds to Verquvo (vericiguat), a prescription medication approved by the FDA in January 2021. It is indicated for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and reduced ejection fraction (HFrEF).
What is the current market landscape?
The global heart failure drugs market was valued at approximately USD 7 billion in 2022, with expected compound annual growth rate (CAGR) of 7-8% through 2030. Key competitors include:
- Entresto (sacubitril/valsartan): Dominates with about 30% market share.
- Corlanor (ivabradine): Holds 10-12%, primarily for specific heart failure cases.
- Other agents: Including beta-blockers and diuretics, account for the remaining market.
Vericiguat's niche is patients with high-risk HFrEF, especially those who have recently experienced hospitalization or worsening symptoms, positioning it as an option for specialized use.
What are the sales trends?
Verquvo's initial sales post-launch in 2021 totaled approximately USD 100 million globally. Sales increased to nearly USD 150 million in 2022, with U.S. sales accounting for the majority. The drug's uptake depends on preferential positioning, payer coverage, and clinical guideline inclusion.
Factors impacting sales:
- Guideline adoption: Pending inclusion in American College of Cardiology/American Heart Association (ACC/AHA) guidelines.
- Payer coverage: Commercial insurers and Medicare fee-for-service have begun covering the drug, but at variable levels.
- Physician adoption: Influenced by regional clinical data and ease of prescribing.
What are the price projections?
Current Pricing:
- Average wholesale price (AWP): USD 370 for a 60-tablet pack.
- Estimated wholesale acquisition cost (WAC): USD 330.
- Patient out-of-pocket (OOP): USD 25-50 with insurance, higher without coverage.
Future pricing considerations:
- Market penetration: As physician familiarity increases, prescriber volume is expected to rise.
- Reimbursement trends: Favorable coverage can stabilize or slightly lower list prices.
- Competitive landscape: Introduction of emerging therapies could exert downward pressure.
Price projections (2023-2030):
| Year |
Estimated USD per pack |
Commentary |
| 2023 |
330 – 370 |
Stabilized at current levels; volume growth key |
| 2024 |
330 – 355 |
Slight downward pressure from expanding competition |
| 2025 |
310 – 340 |
Increased competition; possible price negotiations |
| 2026-2030 |
300 – 330 |
Market saturation; potential generic entry after patent expiry (if applicable) |
Pricing drivers:
- Patent exclusivity: Patent until 2030, limiting generic competition initially.
- Manufacturing costs: Remain stable, with minor reductions expected.
- Regulatory decisions: Favorable guidelines reinforce pricing stability.
What are the regulatory and patent considerations?
Vericiguat patent protection extends through 2030. Any patent challenges or extensions could affect timing for generic entry. Regulatory approval in Europe and other markets may produce price variations.
What are the key risks and opportunities?
Risks:
- Regulatory delays or rejection of additional indications.
- Market competition from newer drugs or biosimilars.
- Reimbursement restrictions reducing patient access.
Opportunities:
- Expanding indications: Potential for use in other heart failure subtypes.
- Guideline adoption increasing prescriber confidence.
- Global expansion: Particularly in Europe and emerging markets.
Key Takeaways:
- Verquvo is positioned within a growing, competitive heart failure market with USD 7 billion in annual sales.
- Sales are still in early growth, with potential to reach USD 500 million annually by 2025.
- Price levels are stable with expected slight declines due to competitive pressures, but patent protection up to 2030 offers a revenue window.
- Market penetration hinges on guideline acceptance and payer coverage expansion.
Frequently Asked Questions
1. How does Verquvo compare to existing heart failure treatments?
Vericiguat offers a novel mechanism (soluble guanylate cyclase stimulator) targeting high-risk HFrEF patients, filling a niche unmet by sacubitril/valsartan or beta-blockers.
2. What are the barriers to market growth?
Limited clinical data compared to established therapies, cautious physician adoption, and variable payer coverage.
3. When might generic versions enter the market?
Patent protection lasts until 2030, with generic entry likely post-2030 unless patent challenges occur earlier.
4. How significant is reimbursement for sales projections?
Critical; broader coverage can accelerate sales growth, while reimbursement hurdles may restrict access and revenue.
5. What are the key regions for expansion?
The U.S. remains the primary market; Europe and other developed nations hold potential, contingent on regulatory approvals.
References
[1] Global Heart Failure Drugs Market Report, 2022.
[2] FDA Approval Fact Sheet for Verquvo, 2021.
[3] Market Research Future, Heart Failure Drugs Market Analysis, 2023.
[4] American College of Cardiology, Heart Failure Guidelines, 2022.
[5] Patents and Exclusivity Data for Vericiguat, 2023.
